ARTICLE | Company News
Cephalon, Ception deal
March 1, 2010 8:00 AM UTC
On Feb. 23, Cephalon exercised its option to acquire Ception for $250 million. Cephalon had 15 days after receiving data on Feb. 18 from a Phase II trial of Cinquil reslizumab to treat eosinophilic a...